Menu

Recent Interviews

Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


John Jeffrey, CEO, Saturn Oil & Gas Inc.

John Jeffrey
CEO | Saturn Oil & Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary, AB (CAN)

jjeffrey@saturnoil.com

+1-587-392-7900

Saturn Oil & Gas CEO John Jeffrey on the future of the company and ESG


15. April 2020 | 08:10 CET

BioNTech, Evotec, EXMceuticals - Stocks with potential

  • Health
Photo credits: pixabay.com

Health is the most important thing in life. The current protective measures around the globe in connection with the spread of the Corona Virus Covid-19 show how great the fear and helplessness is. Above all, this pandemic has highlighted the extent of the global dependence on China as a supplier of medicines or medical ingredients and protective clothing. Supply chains will get shorter. Individuals and societies will be more focused on health and wellness. In view of the time after the current Corona Crisis it is expected that politics and the economy will reorganize and reposition themselves.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Natural medicine for health

EXMceuticals is a young company focused on the extraction of pure medicinal ingredients from the cannabis plant. The listed company has operations in and near Lisbon, Portugal, and plans to supply the enormous European market with high-quality and pure products from there in the future. In the context of the current Corona Crisis and the time after, the team around CEO Jonathan Summers is an ideal platform to serve a product universe that offers people added value based on entirely natural and under-appreciated ingredients.

EXMceutials already has an operational R&D unit for cannabinoids. It is now in the final stages of finishing the detailed design and equipment specification for an EU-GMP purification facility that is currently unique in Europe in terms of scale. The various fields of use for cannabis in modern medicine will become increasingly important and offer attractive growth prospects for the company and therefore it's investors.

Corona vaccine from 2021

BioNTech has been one of the most discussed companies in connection with the development of a vaccine for the prevention of the spread of Covid-19 for several weeks now. The German company works in cooperation with the pharmaceutical giant Pfizer. The vaccine is expected to be available in a high number of doses in 2021. Pfizer is financing the development of the vaccine and BioNTech will subsequently refund 50% of the costs from the expected revenues. The target markets for the vaccine will be Europe and the USA.

Medical innovation service provider

Evotec is active in the research and development of active ingredients. The main focus is on gene therapy. The company develops new technologies and applies them to access more precise and effective drugs. Evotec cooperates with renowned partners around the globe in early phases to increase efficiency in the development of active ingredients as an external innovation service provider. According to Evotec, quality and speed are at the forefront of its collaboration with customers.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. December 2020 | 08:50 CET | by André Will-Laudien

Q & M Dental, Moderna, AstraZeneca: Serving people!

  • Health

Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.

Read

27. October 2020 | 10:17 CET | by André Will-Laudien

Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition

  • Health

By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!

Read

29. September 2020 | 10:51 CET | by Mario Hose

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.

Read